1. Home
  2. SBI vs CCCC Comparison

SBI vs CCCC Comparison

Compare SBI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

HOLD

Current Price

$7.76

Market Cap

109.7M

Sector

Finance

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.50

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBI
CCCC
Founded
1992
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.7M
240.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SBI
CCCC
Price
$7.76
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.50
AVG Volume (30 Days)
39.5K
1.4M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
4.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$30,108,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.96
$1.09
52 Week High
$8.00
$4.70

Technical Indicators

Market Signals
Indicator
SBI
CCCC
Relative Strength Index (RSI) 44.40 49.03
Support Level $7.76 $2.50
Resistance Level $7.84 $2.69
Average True Range (ATR) 0.05 0.18
MACD 0.01 -0.01
Stochastic Oscillator 46.67 23.86

Price Performance

Historical Comparison
SBI
CCCC

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: